Company: IMNN
Filing Date: 2025-05-30
Form Type: PRE 14A
Source: 0001641172-25-013068
Chunk: 47

Company: Imunon, Inc.
Filing Date: 2025-05-30
Form: PRE 14A
Chunk 47
---
 set forth more fully in the Purchase Agreement):

| ● | We                                                                                          
 agreed not to effect or agree to effect any variable rate transactions until one year after 
 the effective date of the Registration Statement, subject to certain exceptions;            |

| ● | We                                                                                            
 agreed not to issue any shares of common stock or common stock equivalents or to file any     
 other registration statement with the SEC (in each case, subject to certain exceptions) until 
 30 days after the effective date of the Registration Statement; and                           |

| ● | We                                                                                          
 agreed to seek stockholder approval in accordance with the applicable rules and regulations 
 of Nasdaq (“Stockholder Approval”) of, and to solicit our stockholders’                     
 affirmative vote for approval of, the issuance of the Warrant Shares at our Annual Meeting, 
 and, if Stockholder Approval is not obtained at the Annual Meeting, to call a meeting every 
 90 days thereafter to seek such Stockholder Approval until the earlier of the date on which 
 Stockholder Approval is obtained or the Warrants are no longer outstanding. This Issuance   
 Proposal is intended to fulfill this final covenant.                                        |

The Engagement Letter

Pursuant to the Engagement Letter, we paid Wainwright a total cash fee equal to 7.0% of the aggregate gross proceeds of the Private Placement, as well as certain expenses, and Brookline received up to 15% of the cash fee. In addition, the Company issued to Wainwright, or its designees, the Placement Agent Warrants to purchase up to an aggregate of 361,111 shares of common stock at an exercise price equal to $0.5625 per share.

The Common Warrants

The Common Warrants are exercisable on or after Stockholder Approval until the three-year anniversary of the Stockholder Approval. The Common Warrants have an exercise price of $0.45 per share. The exercise price and number of shares issuable upon exercise of the Common Warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, subsequent rights offerings, pro rata distributions, reorganizations, or similar events affecting the common stock and the exercise price. Upon any such price-based adjustment to the exercise price, the number of shares issuable upon exercise of the Common Warrants will be adjusted proportionately. The Common Warrants may be exercised for cash, provided that, if there is no effective registration statement available registering resale of the Common Warrant Shares, the Common Warrants may be exercised on a cashless basis.